Sunny Pharmtech Inc. (TPEX:6676)
Taiwan
· Delayed Price · Currency is TWD 20.65
-0.05 (-0.24%)
Feb 21, 2025, 1:43 PM CST
Sunny Pharmtech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 485.01 | 428.83 | 359.59 | 241 | 419.94 | 234.48 | Upgrade
|
| Revenue Growth (YoY) | 27.11% | 19.26% | 49.21% | -42.61% | 79.09% | 64.21% | Upgrade
|
| Cost of Revenue | 203.81 | 143.3 | 152.88 | 125.25 | 195.87 | 139.23 | Upgrade
|
| Gross Profit | 281.2 | 285.53 | 206.71 | 115.75 | 224.07 | 95.25 | Upgrade
|
| Selling, General & Admin | 153.28 | 148.76 | 138.45 | 120.39 | 116.37 | 103.64 | Upgrade
|
| Research & Development | 195.4 | 208.87 | 255.88 | 171.37 | 182.04 | 205.65 | Upgrade
|
| Operating Expenses | 348.68 | 357.62 | 394.33 | 291.75 | 298.41 | 309.29 | Upgrade
|
| Operating Income | -67.47 | -72.1 | -187.62 | -176 | -74.34 | -214.04 | Upgrade
|
| Interest Expense | -9.44 | -11.24 | -4.59 | -5.62 | -6.8 | -8.28 | Upgrade
|
| Interest & Investment Income | 5.04 | 5.73 | 1.38 | 0.36 | 1.48 | 1.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 20.38 | 12.23 | 16.15 | -3.18 | -26.69 | -7.64 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.18 | 3.38 | 4.53 | 3.31 | 2.88 | 2.65 | Upgrade
|
| EBT Excluding Unusual Items | -49.31 | -62 | -170.15 | -181.14 | -103.46 | -226.3 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.08 | -0.08 | -0.09 | - | - | 0.01 | Upgrade
|
| Asset Writedown | -1.24 | -1.24 | - | - | -6.18 | - | Upgrade
|
| Other Unusual Items | - | - | - | 4.48 | 7.89 | - | Upgrade
|
| Pretax Income | -50.48 | -63.32 | -170.24 | -174.79 | -101.76 | -226.3 | Upgrade
|
| Earnings From Continuing Operations | -50.48 | -63.32 | -170.24 | -174.79 | -101.76 | -226.3 | Upgrade
|
| Net Income | -50.48 | -63.32 | -170.24 | -174.79 | -101.76 | -226.3 | Upgrade
|
| Net Income to Common | -50.48 | -63.32 | -170.24 | -174.79 | -101.76 | -226.3 | Upgrade
|
| Shares Outstanding (Basic) | 148 | 143 | 139 | 134 | 129 | 126 | Upgrade
|
| Shares Outstanding (Diluted) | 148 | 143 | 139 | 134 | 129 | 126 | Upgrade
|
| Shares Change (YoY) | 6.71% | 3.04% | 3.60% | 3.29% | 2.70% | 12.64% | Upgrade
|
| EPS (Basic) | -0.34 | -0.44 | -1.23 | -1.31 | -0.79 | -1.80 | Upgrade
|
| EPS (Diluted) | -0.34 | -0.44 | -1.23 | -1.31 | -0.79 | -1.80 | Upgrade
|
| Free Cash Flow | -110.45 | -105.88 | -152.3 | -193.31 | -91.04 | -196.72 | Upgrade
|
| Free Cash Flow Per Share | -0.75 | -0.74 | -1.10 | -1.45 | -0.70 | -1.56 | Upgrade
|
| Gross Margin | 57.98% | 66.58% | 57.48% | 48.03% | 53.36% | 40.62% | Upgrade
|
| Operating Margin | -13.91% | -16.81% | -52.18% | -73.03% | -17.70% | -91.28% | Upgrade
|
| Profit Margin | -10.41% | -14.77% | -47.34% | -72.53% | -24.23% | -96.51% | Upgrade
|
| Free Cash Flow Margin | -22.77% | -24.69% | -42.35% | -80.21% | -21.68% | -83.90% | Upgrade
|
| EBITDA | 49.37 | 41.34 | -83.09 | -76.24 | 26.9 | -120.87 | Upgrade
|
| EBITDA Margin | 10.18% | 9.64% | -23.11% | -31.63% | 6.41% | -51.55% | Upgrade
|
| D&A For EBITDA | 116.84 | 113.44 | 104.53 | 99.76 | 101.24 | 93.17 | Upgrade
|
| EBIT | -67.47 | -72.1 | -187.62 | -176 | -74.34 | -214.04 | Upgrade
|
| EBIT Margin | -13.91% | -16.81% | -52.18% | -73.03% | -17.70% | -91.28% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.